Role of hepatocyte growth factor and its receptor c-met in multiple myeloma

Medical Oncology

Volumn 15, Issue 3, 1998, Pages 145-153

  Seidel, Carina ^a,b   Børset, Magne ^a   Hjorth Hansen, Henrik ^a   Sundan, Anders ^a   Waage, Anders ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Bone; C met; Hepatocyte growth factor; Myeloma

Indexed keywords

CYTOKINE; GROWTH FACTOR RECEPTOR; PROTEOHEPARAN SULFATE; SCATTER FACTOR;

BONE METABOLISM; GENE EXPRESSION; HOMEOSTASIS; HUMAN; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL;

EID: 0031788989     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02821933     Document Type: Review

References (72)

1. Mundy GB. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 291.
2. Garrett IR et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987; 317: 526-532.
3. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-518.
4. Dinarello CA. Biology of interleukin 1. FASEB J 1988; 2: 108-115.
5. Corboz VA et al. Effect of macrophage colony-stimulating factor on in vitro osteoclast generation and bone resorption. Endocrinology 1992; 130: 437-442.
6. Ishimi Y et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990; 145: 3297-3303.
7. Lowik CW et al. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Comm 1989; 162: 1546-1552.
8. Udagawa N et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med 1995; 182: 1461-1468.
9. Borset M et al. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996; 271: 24655-24661.
10. Borset M, Hjorth Hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996; 88: 3998-4004.
11. Seidel C et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998; 91: 806-812.
12. Hofmann R, Joseph A, Bhargava MM, Rosen EM, Goldberg I. Scatter factor is a glycoprotein but glycosylation is not required for its activity. Biochem Biophys Acta 1992; 1120: 343-350.
13. Gak E, Taylor WG, Chan AM, Rubin JS. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett 1992; 311: 17-21.
14. Nakamura T et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-443.
15. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987; 327: 239-242.
16. Rosen EM, Goldberg ID, Kacinski BM, Buckholz T, Vinter DW. Smooth muscle releases an epithelial cell scatter factor which binds to heparin. In Vitro Cell Dev Biol 1989; 25: 163-173.
17. Nakamura S, Gohda E, Matsunaga T, Yamamoto I, Minowada J. Production of hepatocyte growth factor by human haematopoietic cell lines. Cytokine 1994; 6: 285-294.
18. Watanabe S et al. Hepatocyte growth factor accelerates the wound repair of cultured gastric mucosal cells. Biochem Biophys Res Comm 1994; 199: 1453-1460.
19. Tsao MS et al. Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ 1993; 4: 571-579.
20. Bussolino F et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629-641.
21. Rubin JS et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 1991; 88: 415-419.
22. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. Proc Natl Acad Sci USA 1994; 91: 4357-4361.
23. Otonkoski T et al. Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells. Diabetes 1994; 43: 947-953.
24. Kataoka H et al. Stimulation of DNA synthesis in skin fibroblasts by human hepatocyte growth factor/scatter factor. Cell Biol Int 1993; 17: 65-73.
25. Uehara Y et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995; 373: 702-705.
26. Schmidt C et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373: 699-702.
27. Bottaro DP et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
28. Galimi F et al. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol 1994; 127: 1743-1754.
29. Kmiecik TE, Keller JR, Rosen E, Vande Woude GF. Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. Blood 1992; 80: 2454-2457.
30. Park M et al. Mechanism of met oncogene activation. Cell 1986; 45: 895-904.
31. Cooper CS et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311: 29-33.
32. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990; 111: 2097-2108.
33. Takayama H et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 1997; 94: 701-706.
34. Natali PG et al. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 1993; 68: 746-750.
35. Beilmann M et al. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood 1997; 90: 4450-4458.
36. Di Renzo MF et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 1994; 58: 658-662.
37. Rong S et al. Met expression and sarcoma tumorigenicity. Cancer Res 1993; 53: 5355-5360.
38. Weimar IS et al. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 1997; 89: 990-1000.
39. Jucker M et al. The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma. Leuk Res 1994; 18: 7-16.
40. Di Renzo MF et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6: 1997-2003.
41. Nakamura S, Gohda E, Matsuo Y, Yamamoto I, Minowada J. Significant amount of hepatocyte growth factor detected in blood and bone marrow plasma of leukaemia patients. Br J Haematol 1994; 87: 640-642.
42. Hjort-Hansen H, Seidel C, Børset M, Lamvik J, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukemia. (submitted).
43. Joshua DE, Brown RD, Gibson J. Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease. Leuk Lymphoma 1994; 15: 375-381.
44. Blade J et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88: 117-121.
45. Oivanen TM. Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 1996; 92: 834-839.
46. Joshua DE et al. Multiple Myeloma: plateau phase revisited. Hem Rev 1991; 5: 59-66.
47. Salmon SE, Smith BA. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest 1970; 49: 1114.
48. Tsarfaty I et al. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science 1994; 263: 98-101.
49. Rong S et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol 1992; 12: 5152-5158.
50. Bellusci S et al. Creation of an hepatocyte growth factor/ scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994; 9: 1091-1099.
51. Bataille R et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989; 7: 1909-1914.
52. Taube T et al. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992; 49: 192-198.
53. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974; 136: 2348.
54. Grano M et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA 1996; 93: 7644-7648.
55. Fuller K, Owens J, Chambers TJ. The effect of hepatocyte growth factor on the behaviour of osteoclasts. Biochem Biophys Res Comm 1995; 212: 334-340.
56. Sato T et al. Hepatocyte growth factor is involved in formation of osteoclast-like cells mediated by clonal stromal cells (MC3T3-G2/PA6). J Cell Physiol 1995; 164: 197-204.
57. Eriksen EF et al. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 1993; 8: 127-132.
58. Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF. Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 1994; 24: 81-94.
59. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989; 1: 27-35.
60. Liebersbach BF, Sanderson RD. Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 1994; 269: 20013-20019.
61. Ridley RC et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood 1993; 81: 767-774.
62. Zioncheck TF et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem 1995; 270: 16871-16878.
63. Naka D, Ishii T, Shimomura T, Hishida T, Hara H. Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. Exp Cell Res 1993; 209: 317-324.
64. Schwall RH et al. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J Cell Biol 1996; 133: 709-718.
65. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 1994; 269: 11216-11223.
66. Matsumoto K, Tajima H, Okazaki H, Nakamura T. Heparin as an inducer of hepatocyte growth factor. J Biochem (Tokyo) 1993; 114: 820-826.
67. Matsumoto K, Nakamura T. Heparin functions as a hepatotrophic factor by inducing production of hepatocyte growth factor. Biochem Biophys Res Comm 1996; 227: 455-461.
68. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170: 1315-1320.
69. Douketis JD et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost 1996; 75: 254-257.
70. Shefras J, Farquharson RG. Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol Reprod Biol 1996; 65: 171-174.
71. Fuller K, Chambers TJ, Gallagher AC. Heparin augments osteoclast resorption-stimulating activity in serum. J Cell Physiol 1991; 147: 208-214.
72. Caligaris Cappio F et al. Bone marrow microenvironment and the progression of multiple myeloma. Leuk Lymphoma 1992; 8: 15-22.